Nath Bio-Genes (India): Unaudited Standalone and Consolidated Financial Results as on 30th September 2026

What happened

Nath Bio-Genes (India) (NATHBIOGEN) filed a disclosure with the exchanges on 14 November 2026 at 05:13 PM titled "Unaudited Standalone and Consolidated Financial Results as on 30th September 2026".

From the filing: "We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on Saturday 14 th November 2026, has approved the Standalone and Consolidated unaudited financial results, for the quarter and half year ended 30 th September, 2026."

Company snapshot

Nath Bio-Genes (India) is a micro-cap company, with a market value of about ₹268 crore.

The stock last traded at ₹140.9, against a 52-week range of ₹126.2–₹204 (30.9% below the high).

Before this filing the shares had moved +4.0% over the month and −8.8% over three months. Average daily turnover over the last 20 sessions was about ₹0.08 crore.

Promoters held 45.60% at the end of Q1 FY27; 13.78% of promoter shares were pledged. Foreign institutions owned 0.27% and domestic institutions 0.01%.

What history shows

BCEIE's records show 1 previous results filing from the company since May 2026.

Market-wide, 11,788 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 43% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Management commentary, margins and order book or guidance in the investor presentation.
• 14 November 2026: Board meeting — Financial Results.

Source

• Exchange filing (PDF)